Podcasts about transplantation

AJT December 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Hannah Bahakel to discuss the key articles of the December issue of the American Journal of Transplantation. Hannah Bahakel is a Clinical Immunodeficiency fellow at Cincinnati Children's Hospital Medical Center [03:34] Higher vs standard mean arterial pressure target in the immediate postoperative period of liver transplantation to prevent acute kidney injury: A randomized clinical trial (LIVER-PAM) [13:51] Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies [26:27] Tolerogenic lung allograft microenvironment suppresses pathogenic tissue remodeling following respiratory virus infection in mice [37:11] Therapeutic needs in solid organ transplant recipients: The American Society of Transplantation patient survey [48:19] Impact of kidney function on 200 days of antiviral prophylaxis for cytomegalovirus disease in cytomegalovirus-seronegative recipients of cytomegalovirus-seropositive donor kidneys: Post hoc analysis of a randomized, phase 3 trial of letermovir vs valganciclovir prophylaxis

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

An in vivo brain organoid platform reveals how human neurons and glia interact across development, aging, and disease. Fred H. Gage, Ph.D., generates three dimensional organoids from induced pluripotent stem cells and examines their maturation, synapses, and network activity with two-photon imaging and single-cell profiling. Gage integrates human microglia and astrocytes to study immune signaling, injury responses, and support functions that shape circuit behavior. Transplantation enables vascularization, reduces cell death, and yields features consistent with a blood brain barrier. Analyses identify diverse astrocyte types and trajectories, while patterns of tau expression inform Alzheimer's disease modeling. Gage also converts adult fibroblasts into age retaining neurons that assemble into 3D spheroids, creating complementary models to connect genes, cells, and circuits with pathology and to guide strategies for prevention and therapy. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41160]

In this episode of Lab Rats to Unicorns, John Flavin sits down with Dr. Joseph Leventhal, Professor of Surgery and Director of Living Donor Kidney Transplantation at Northwestern University Feinberg School of Medicine. A pioneer in the field of organ transplantation, Dr. Leventhal's research is redefining what's possible in immune tolerance—an area often described as the “holy grail” of transplantation, where a patient's body can accept a donated organ without lifelong immunosuppressive drugs.Dr. Leventhal shares his journey from growing up in New York City to becoming one of the foremost leaders in transplant surgery and cell therapy innovation. He discusses how his team's groundbreaking clinical work has shown that tolerance can be achieved through cellular therapies, potentially freeing patients from the burdens of chronic immunosuppression.From the early days of cyclosporine to founding TRACT Therapeutics and developing first-in-human T-regulatory cell therapies, Joe reflects on the scientific curiosity, resilience, and collaboration that drive progress in a complex field. He also explores the evolving ecosystem for biotech innovation in Chicago, the challenges of translating academic research into clinical therapies, and the optimism surrounding the next generation of precision cell therapies.

In this episode, Prof. Fanny Mochel discusses the rationale and key findings from a retrospective cohort study of patients with CSF1R-related disorder treated with hematopoietic stem cell transplantation, highlighting the potential of this therapy to achieve both clinical and radiological disease stabilization. Journal CME is available until September 24, 2026 Read the article.

This week on Health Matters, Courtney talks with Dr. Robert Brown, the chief of gastroenterology and hepatology at NewYork-Presbyterian and Weill Cornell Medicine, to discuss the benefits and risks of taking dietary supplements, for our liver and our overall health. Dr. Brown offers tips for deciding which supplements to take, which to avoid, and ways we can optimize our liver health. ___Dr. Robert Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. He co-founded the Center for Liver Disease and Transplantation at NewYork-Presbyterian/Weill Cornell Medical Center, a joint program with Columbia University Irving Medical Center, in 1998. Dr. Brown will continue as medical director of this program, the largest for liver transplantation in New York City.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

En France, plus de 90 000 personnes souffrent d'insuffisance rénale chronique terminale et ce nombre a considérablement augmenté ces dernières années. La transplantation rénale est l'option thérapeutique privilégiée pour les patients atteints d'IRCT, car elle offre des avantages substantiels en termes d'amélioration de l'espérance de vie et de la qualité de vie des patients. En France, seulement 4% des patients atteints d'IRCT reçoivent chaque année une transplantation rénale, tandis que la plupart d'entre eux restent en dialyse. 94% en hémodialyse et seulement 6% en dialyse péritonéale 1. Dans l'attente d'une greffe rénale, les patients sont donc amenés à dialyser. Mais quelle modalité choisir en pré-transplantation ? Pour répondre à cette question, nous avons aujourd'hui le privilège d'accueillir le docteur Séverine Baudreuil, néphrologue à l'hôpital Bicêtre. Référence : 1. Rapport REIN 2021   Invitée : Dr. Séverine Beaudreuil (Néphrologue, Le Kremlin-Bicêtre, APHP) Le Dr Beaudreuil déclare n'avoir aucun lien d'intérêt avec le sujet traité. L'équipe :
 Animation :  Pyramidale Communication Production : Pyramidale Communication Crédits : Pyramidale Communication, Sonacom   Ce podcast est uniquement destiné à des fins d'information. Si vous souhaitez contacter Baxter pour de plus amples informations ou pour signaler un événement indésirable, veuillez consulter notre site web à l'adresse suivante : https://www.baxter.fr/fr/contact-us   FR-RC00-240025 V1.0

CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies evaluation with Dr. Michelle Kittleson, Professor of Medicine and Director of Education in Heart Failure and Transplantation at Cedars-Sinai. In this case-based discussion, they cover the signs and symptoms of end-stage heart failure, the initial management strategies, and the diagnostic workup required when considering advanced therapies. Importantly, they discuss the special considerations for pursuing left-ventricular assist device (LVAD) versus heart transplantation as well as the multidisciplinary, team-based approach needed when advanced therapies are indicated.  Notes were drafted by Dr. Shazli Khan.  Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Guideline-directed medical therapy (GDMT) is indicated in all heart failure patients and improves survival, but progressive symptoms and intolerance to GDMT can be warning signs of disease progression. The I-NEED-HELP mnemonic is an excellent reference when considering referral for advanced therapies (Figure).   Management of acute decompensation includes diuretics and possible inotropic support. The inotropic agent used should be whichever best suits your specific patient. Milrinone may result in more hypotension, whereas dobutamine may result in more tachycardia. Tachycardic and normotensive patients may do better with milrinone, while hypotensive patients with normal heart rates may do better with dobutamine. Notably, DoReMi found no difference between milrinone and dobutamine for patients with cardiogenic shock.  The initial diagnostic evaluation includes an echocardiogram, right heart catheterization (RHC), and often cardiopulmonary exercise testing (CPET) to objectively assess the status of the heart. Comprehensive labs, imaging and cancer screening are also needed to assess all other organs.   When making the decision to pursue advanced therapies, always ask:   Is the heart sick enough?   Is the rest of the body well enough?   These two questions provide a framework to guide if patients are optimal candidates for transplant versus LVAD.   The advanced therapies evaluation is a team sport! Patients will meet not only with advanced heart failure cardiologists, but also cardiac surgeons, psychiatrists, social workers, nutritionists and pharmacists. All team members are of critical value in the process.   Notes 1.) What are the key features of advanced cardiomyopathy, and when should providers consider referral for advanced therapies?   Advanced cardiomyopathy may present as recurrent hospitalizations for decompensated heart failure, intolerance to GDMT with symptomatic orthostasis and hypotension, and progressive symptoms of heart failure despite medical therapy.   The I-NEED-HELP mnemonic is a helpful tool to identify patients at risk of heart failure and is defined as follows: Need for Inotropic support, New York Heart Association (NYHA) Class IV symptoms, End-Organ Dysfunction, Ejection fraction

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Christie Rampersad to discuss the key articles of the November issue of the American Journal of Transplantation. Christie Rampersad is clinical associate, in the Division of Nephrology at the University of Toronto in the Ajmera Transplant Centre [03:45] The early impacts of an attempt to standardize kidney procurement biopsy practices [13:40] The current state of simultaneous heart-liver transplantation in the United States [20:11] Engaging patients in organ transplant listing meetings: A survey study [37:32] Single-cell transcriptional landscape of liver transplant rejection reveals tissue persistence of clonally expanded, treatment-resistant T cells [45:32] Infectious disease surveillance and management in clinical xenotransplantation: Experience with the first human porcine kidney transplant

Gastrointestinal complications are common—but often underrecognized—after lung transplantation. From diarrhea and nausea to malabsorption and poor appetite, these challenges can seriously impact recovery and long-term health outcomes.In this episode of the DNS Podcast, host Christina Rollins speaks with Bridget Doyle, MS, RD, LDN, CNSC, a transplant dietitian specializing in lung transplant nutrition. Bridget shares her expertise on identifying, managing, and supporting patients through complex GI issues post-transplant.Listeners will gain insights on:✅ The most frequent GI complications following lung transplant✅ How medications like immunosuppressants and antibiotics affect digestion✅ Practical nutrition strategies for diarrhea, nausea, and poor intake✅ Food safety guidance for immunocompromised patients✅ When to consider enteral or parenteral nutrition support✅ Key labs and nutrients to monitor for optimal recoveryTune in to hear evidence-based strategies for improving GI health and supporting successful long-term outcomes for transplant recipients. Visit us at dnsdpg.org to learn more.

This bonus content is a reading from Platypus, the CASTAC Blog. The full post by Juliana Vieira can be read at https://blog.castac.org/2025/10/uterus-transplantation-a-scientific-advance-or-the-reflection-of-gender-stereotypes/. About the post: After all, to what extent do highly innovative medical technologies, such as uterus transplantation, cease to express a progressive vision of the future and instead reinforce morally conservative values related to motherhood, gender, and gestation? (This episode is available in additional languages on Platypus, The CASTAC Blog.)

Professor Matteo Iannacone is Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at Vita-Salute San Raffaele University. His work centers on understanding the generation of dysfunctional adaptive immune cells in chronic hepatitis B virus infection and developing new strategies to reprogram them into functional cells endowed with potent antiviral activity.

Cool air and warm soils mean that it's a great time to divide and multiply the plants that you love, and Leslie and Marianne want to help you do it easily, efficiently, and with the least amount of plant pain as possible. What are they dividing in their gardens and how are they doing it? And why is it so good for the plants to rip them from happy homes just when they were thinking of taking a well-earned nap? For that matter, why aren't the girls sipping pumpkin lattes and waiting ‘till spring? Set down that bulb planter and grab those two forks, because it's all about FREE this week on The Garden Mixer. (Just for the record Marianne hates pumpkin lattes. Leslie's a fan.)___________________Be sure to hit the subscribe button so we can keep you smiling while you hit the mess [your garden] out there.Full Show Notes at⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠The Garden Mixer Podcast's Substack⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠____________________Socials – Pick Your Platform:Follow us on Instagram⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@thegardenmixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Indulge us on TikTok⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@the.garden.mixer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spar with us on X⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠@gardenmixerpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠“French Bistro” theme by Adieu Adieu. License D0LZBINY30GGTBBW

Première européenne: transplantation cardiaque partielle réussie chez un enfant Les brèves du jour Le bric à brac de Sapiens 5/5: un artiste nommé Sapiens "Vaccinez-moi" (2025) d'Alex Fredo pour parler des vaccins

It seems like every week, there's a new headline about some kind of sci-fi-esque organ transplant. Think eyeballs, 3D-printed kidneys, pig hearts.In her new book, Replaceable You: Adventures in Human Anatomy, science writer Mary Roach chronicles the effort to fabricate human body parts—and where that effort sometimes breaks down. Host Flora Lichtman speaks with Roach about everything from hair transplants to 3D-printed hearts, and why our anatomy is so hard to replicate in the first place.Guest: Mary Roach is a science writer and the author of Replaceable You: Adventures in Human Anatomy.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Dans cet épisode, on lève le voile sur un sujet méconnu mais essentiel : le don de tissus humains. Caroline, coordonnatrice en prélèvement et développement, et Jimmy, spécialiste en tissus humains, nous expliquent comment ces dons peuvent transformer des vies, et pourquoi il est crucial d'en parler. Un échange éducatif, humain et sans filtre.  Nous vous rappelons que, si vous consentez au don de tissus, vous pouvez dès maintenant signer votre carte d'assurance maladie (RAMQ). L'autocollant à apposer sur la carte peut être commandé en ligne sur https://publications.msss.gouv.qc.ca/msss/document-000065/ ou encore, il vous sera remis lors du renouvellement de votre carte. Il est également essentiel d'en discuter avec vos proches afin de clarifier les volontés et décisions de chacun.  Le jeu de Carte Héma-Québec "La question qui tue pas" sera disponible, jusqu'à épuisement des stock, dans les Centres de dons Héma-Québec. 

Liver transplantation continues to evolve as strategies expand to address organ shortage and optimize outcomes. Normothermic machine perfusion (NMP) offers a novel way to preserve and assess donor livers prior to implantation. In this episode of Behind the Knife, our transplant team at University of Nebraska Medical Center discusses the latest evidence from randomized trials, practical applications in donation after circulatory death (DCD) grafts, and how NMP is shaping clinical decision-making in high-risk transplants.  Hosts -  Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan   - Jacqueline Dauch, MD, Assistant Professor, University of Nebraska Medical Center  -  Shaheed Merani, MD PhD, Associate Professor, University of Nebraska Medical Center  - Alan Langnas, DO, Professor, University of Nebraska Medical Center  Learning Objectives - Describe the principles of normothermic machine perfusion (NMP) and how it differs from static cold storage.  - Summarize the design and key outcomes of the PROTECT trial and the Chapman et al. trial on NMP in liver transplantation.  - Recognize the clinical scenarios where NMP provides the greatest benefit, particularly in high-risk grafts (e.g., DCD donors, high donor risk index).  - Apply a practical viability assessment framework for livers on NMP, including hemodynamics, bile production, lactate trajectory, and histology when indicated.  - Discuss the implications of NMP for allocation, system logistics, and future adoption trends in transplantation.  References   1.     Markmann JF, Abouljoud MS, Ghobrial RM, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 2022;157(3):189-198. doi:10.1001/jamasurg.2021.6781. https://pubmed.ncbi.nlm.nih.gov/34985503/ 2.     Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic machine perfusion of donor livers for transplantation in the United States: a randomized controlled trial. Ann Surg. 2023;278(5):e912-e921. doi:10.1097/SLA.0000000000005934. https://pubmed.ncbi.nlm.nih.gov/37389552/ 3.     Nasralla D, Coussios CC, Mergental H, et al; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. doi:10.1038/s41586-018-0047-9. https://pubmed.ncbi.nlm.nih.gov/29670285/ 4.     Brubaker AL, Sellers MT, Abt PL, et al. US liver transplant outcomes after normothermic regional perfusion vs standard super rapid recovery. JAMA Surg. 2024;159(6):677-685. doi:10.1001/jamasurg.2024.0520. https://pubmed.ncbi.nlm.nih.gov/38568597/ 5.     Wall A, Snoddy M, Du J, et al. The current landscape of in situ and ex situ machine perfusion utilization for liver grafts from cardiac donation after circulatory death donors in the US. Am J Transplant. 2025;25(3):574-582. doi:10.1016/j.ajt.2024.09.012. https://pubmed.ncbi.nlm.nih.gov/39293517/ 6.     Watson CJE, Gaurav R, Fear C, Swift L, Selves L, Ceresa CDL, Upponi SS, Brais R, Allison M, Macdonald-Wallis C, Taylor R, Butler AJ. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation. 2022 Dec 1;106(12):2391-2398. doi: 10.1097/TP.0000000000004263. https://pubmed.ncbi.nlm.nih.gov/36044364/ 7.     Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, Crick K, Wigmore SJ, Fear C, Cornateanu S, Randle LV, Terrace JD, Upponi S, Taylor R, Allen E, Butler AJ, Oniscu GC. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 2019 Jun;19(6):1745-1758. doi: 10.1111/ajt.15241. https://pubmed.ncbi.nlm.nih.gov/30589499/ 8.     Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091.https://pubmed.ncbi.nlm.nih.gov/20677285/  9.     Kwong AJ, Kim WR, Lake JR, Schladt DP, Handarova D, Howell J, Schumacher B, Weiss S, Snyder JJ, Israni AK. OPTN/SRTR 2023 Annual Data Report: Liver. Am J Transplant. 2025 Feb;25(2S1):S193-S287. doi: 10.1016/j.ajt.2025.01.022. https://pubmed.ncbi.nlm.nih.gov/39947804/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Send us a textDr. Michael McCullar, PhD is Chief Executive Officer  of RegCell ( https://regcellbio.com/ ), a biotechnology company has developed a best-in-class proprietary platform that allows the generation of epigenetically reprogrammed antigen-specific regulatory T-cells (Tregs) that are stable in vivo and maintain a high degree of functionality (S/F-Epigen-Tregs) to restore immune tolerance and ultimately reverse autoimmune disorders as well as the limitations with transplantation.Dr. McCullar has a wealth of experience in the biotech and pharmaceutical industries, spanning more than two decades. Throughout his career, he has been involved in various aspects of drug development and played pivotal roles in the success of several pharmaceutical companies. Dr. McCullar formerly served as the CEO of OnQuality Pharmaceuticals, where he provided executive leadership to this targeted oncology supportive therapy company focused on developing pioneering medications tailored to address the intricacies of cancer treatment-related toxicities. Before that, he was Chief Operating Officer at Tolero Pharmaceuticals, where he had a prominent role in the company's acquisition by Sumitomo Dainippon Pharma and also served as the Senior Vice President of Business Development at Astex Pharmaceuticals, during it's acquisition by Otsuka Pharmaceuticals. Dr. McCullar has held several high-level executive positions at SuperGen, showcasing his commitment and upward career path within the company. His journey at SuperGen culminated in the role of Senior Vice President of Strategy and Operations, where his expertise paved the way for the U.S. Food and Drug Administration (FDA) approval of Dacogen as a treatment for myelodysplastic syndromes, and the acquisition of Astex Therapeutics, which resulted in the formation of Astex Pharmaceuticals, Inc.Dr. McCullar holds a Ph.D. in Toxicology from the University of California, Riverside and an MBA from the W.P. Carey School of Business at Arizona State University.#MichaelMcCullar #RegCell #RegulatoryTCells #Tregs #AutoimmuneDisorders #Transplantation #ShimonSakaguchi #ImmuneSystem #SelfAntigens #Tolerance #AntiInflammatoryCytokines #AntigenPresentingCells #Thymus #BoneMarrow #Anergy #AntigenSpecificTregs #AntigenTargeting #Homing #EpigeneticEditing #Reprogramming #AutologousManufacturing #Japan #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

A panel of oncology pharmacists discusses the role oflifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors. Featuring Brooke Adams, PharmD, BCOP Natalie Brumwell, PharmD, BCOP Bryant A. Clemons, PharmD, BCOP In a special co-branded episode between Oncology On theGo, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosinginterleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses. Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x 

Return to Sport After Meniscal Allograft Transplantation in Collegiate and Professional Athletes Sachs JP, Mufti YN, Rubin J, et al. Am J Sports Med. 2025 Sep 3. doi:10.1177/03635465251366445 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest VALD MoveHealth - https://movehealth.me/ Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux  

In a special co-branded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program, ASTCT Talks, for American Pharmacists Month, a panel of oncology pharmacists discussed optimal strategies for using cellular therapies as treatment for patients with solid tumors. The panel included Brooke Adams, PharmD, BCOP, a board-certified oncology pharmacist specializing in stem cell transplantation and cellular therapy at the Orlando Health Cancer Institute in Orlando, Florida; Natalie Brumwell, PharmD, BCOP, a board-certified oncology pharmacist specializing in cellular therapy at Memorial Sloan Kettering Cancer Center in New York, New York; and Bryant A. Clemons, PharmD, a board-certified oncology pharmacist specializing in hematology, blood and marrow transplantation, and cellular therapy at the University of Kentucky's Markey Cancer Center in Lexington, Kentucky. The discussion focused on the use of the first commercially available tumor-infiltrating lymphocytes (TILs) for patients with unresectable or metastatic melanoma, lifileucel (Amtagvi), which the FDA granted accelerated approval status to in February 2024.1 The panelists first reviewed supporting data from the phase 2 C-144-01 trial (NCT02360579), in which lifileucel demonstrated an objective response rate of 31.5% (95% CI, 21.1%-43.4%), and a median duration of response that was not reached (NR; 95% CI, 4.1 months-NR) at the time of the approval. Additionally, the group highlighted considerations for dosing interleukin-2 (IL-2), including management of toxicities and when to hold or discontinue further doses.  Following a thorough breakdown of the proper conditions for using lifileucel in melanoma, the panelists concluded by discussing how to build upon an “exciting time for cellular therapy in solid tumors.” As part of optimizing the dosing of lifileucel and other cellular therapies in these patient populations, the experts exchanged ideas on how practices can collaborate across institutions and departments to expand access to novel treatments while helping providers develop comfort in administering these agents. Reference FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. News release. FDA. February 16, 2024. Accessed September 30, 2025. https://tinyurl.com/2kweca6x

This week we review a recent multicenter, randomized trial pitting 2 different immunosuppressive therapeutic approaches against each other. How did a novel approach of everolimus + low dose tacrolimus compare to more standard MMF + standard, higher dose tacrolimus in avoidance of major adverse transplant events or complications? How did this first ever prospective trial in the pediatric heart transplantation world start and how difficult was it to perform in the absence of corporate or NIH support? Why can these data help inform FDA labelling for this novel approach and why is this important? Dr. Kevin Daly of Boston Children's Hospital shares his deep insights into this work this week!DOI: 10.1001/jama.2025.14338

In this episode of ASTCT Talks, Dr. Taha Al-Juhaishi is joined by Dr. Filippo Milano, director of the Cord Blood Transplant Program at Fred Hutch, for a wide-ranging conversation on the evolving role of umbilical cord blood transplantation. From its historical milestones to emerging clinical strategies, Dr. Milano shares insights drawn from decades of research, practice and mentorship. The discussion explores the unique biological advantages of cord blood, including its potent graft-versus-leukemia effect and low incidence of chronic GVHD. Dr. Milano outlines ideal patient profiles, unit selection criteria and conditioning regimens, while addressing challenges like engraftment delays and infection risk. As the field looks ahead, Dr. Milano reflects on theimportance of inclusivity, scientific rigor and mentorship to reengage transplant centers and inspire the next generation of clinicians. Whether as a stand-alone therapy or part of a hybrid platform, cord blood transplantation continues to offer hope for patients with high-risk disease and limited donor options.

Spenderorgane sind rar und begehrt. Daher werden auch Tiere zu Organspendern. Noch ist die Xenotransplantation im Versuchsstadium. Doch das Forschungsfeld macht enorme Fortschritte. (00:32) Tierorgane werden immer menschlicher und die Überlebenschancen von Transplantierten immer grösser. Gentechnik macht es möglich, dass die Verpflanzung von tierischen Organen allmählich zu einer realistischen Alternative wird. Bereits schon ein halbes Jahr lebt ein Mensch, der eine Schweineniere erhalten hat. Vor kurzem wurde erstmals eine Schweinelunge in einen Menschen verpflanzt. Eine besonders komplizierte Transplantation. Jetzt versammeln sich Wissenschaftler:innen in Genf zur internationalen Xenotransplantations-Konferenz IXA (Irène Dietschi) (06:42) Meldungen: - Neue Neurblastom-Therapie aus Zürich - Erste Gentherapei gegen Chorea Huntington - Gigantische Felsenkunst in der Arabischen Wüste (Katharina Bochsler (15:37) Zwei Vulkane haben ein unterirdisches Verhältnis Anfang 2025 hat es auf Santorini tüchtig gerumpelt. Eine Reihe von Erdbeben bewegte die Inselgruppe in der südlichen Ägäis. Der Vulkan unterhalb des Kykladen-Archipels war spürbar unruhig geworden. Und nicht nur er, wie sich jetzt zeigt. Mitgewirkt hat auch der sieben Kilometer entfernte submarine Vulkan Kolumbos. Denn Forschende haben jetzt entdeckt: die beiden Vulkane teilen sich eine gemeinsame Magmakammer (Anita Vonmont) (21:16) Das Konzept der wasserreichen Exoplaneten verdampft Eine ETH-Studie widerlegt die Hypothese, wonach weit draussen im Kosmos von riesigen Ozeanen bedeckte - sogenannt hyzänische - Planeten kreisen. Dieses Konzept bewohnbarer Exoplaneten schürte in den letzten Jahren die Hoffnung, Leben im All zu finden. Forschende der ETH Zürich kommen nun zum Schluss: Diese «Wasserwelten» sind wohl nur Fiktion. In der Realität würde ein Grossteil des Wassers bald nach der Geburt der Planeten durch chemische Prozesse verschwinden. (Sandro Della Torre) LINKS Xenotransplantation IXA Konferenz: ixa2025.org Neuroblastom: nature.com/articles/s41586-025-09564-0 Gentherapie Chorea Huntington: uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii Planetary health Check: planetaryhealthcheck.org Kosmische Wasserwelten: iopscience.iop.org/article/10.3847/2041-8213/adff73

AJT October 2025 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Christina Haugen to discuss the key articles of the October issue of the American Journal of Transplantation. Dr. Christina Haugen is an Assistant Professor of Surgery at the University of Cincinnati. [03:28] Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes—An analysis of COMPARE trial data [10:26] Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation [19:21] Potential targeting of urokinase-type plasminogen activator receptor–formyl peptide receptor signaling to prevent recurrence in posttransplant primary podocytopathies [30:20] The relationship between cessation of brain and systemic circulation after withdrawal of life-sustaining measures [36:03] Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Hosts Roz and Dr. Sanchez-Fueyo discuss the key articles of the September issue of the American Journal of Transplantation. [03:30] Blunted cardiac reserve as a marker of cirrhotic cardiomyopathy—Cardiac outcomes following liver transplantation and comparison to the existing guidelines [14:18] Back-table intra-arterial administration of C1 esterase inhibitor to deceased donor kidney allografts improves posttransplant allograft function: Results of a randomized double-blind placebo-controlled clinical trial [25:55] Donor-derived cell-free DNA is associated with the degree of immunosuppression in lung transplantation [36:24] A two-threshold algorithm using donor-derived cell-free DNA fraction and quantity to detect acute rejection after heart transplantation [45:00] Cell therapy with human Interleukin 10–producing ILC2s enhances islet function and inhibits allograft rejection

In this episode, we are joined by Dr. Emile Bacha to discuss the emerging field of partial heart transplantation. The conversation explores the history of the concept, its reintroduction in recent years, and how techniques such as domino procedures are being developed to expand donor availability. Dr. Bacha explains the practical challenges of regulation, organ procurement, and immunosuppression, as well as early outcomes seen in paediatric patients. With reflections on valve durability, patient growth, and the future potential of this approach, this episode offers a detailed look into a promising area of congenital cardiac surgery and beyond.

Vidcast:   https://www.instagram.com/p/DNd6KltPeD_/Transplantation immuno-geneticists at Sweden's Uppsala University Hospital have successfully used gene editing to modify human pancreatic islet cells such that these transplants are more histocompatible, survive longer, and function better.  Their single patient case report appeared in a recent issues of the New England Journal of Medicine.The recipient is a 42-year-old male juvenile-onset insulin-dependent diabetic. The researchers utilized CRISPR-Cas12b gene editing technology to delete genes that code for incompatible cell surface antigens while adding genes coding for protective antigens thereby making the donor pancreatic cells invisible to the recipient's immune system.Over a 12-week period, the limited number of gene-edited islet cells available for transplantation were able to reduce but not totally eliminate the recipients insulin requirement.  This proved the viability and functional integrity of the transplanted islet cells suggesting that transplantation of a larger complement of islet cells could provide a recipient's total insulin requirement therapy curing diabetes without the need for ongoing immunosuppression with its often toxic side effects.https://medicalxpress.com/news/2025-08-gene-islet-transplant-human-functional.htmlhttps://www.nejm.org/doi/10.1056/NEJMoa2503822#diabetes #insulin #isletcells #transplantation #geneediting #immunosuppression

Sonja Koppitz www.deutschlandfunkkultur.de, Plus Eins

In this week's replay episode from 3 years ago, we delve into the world of pediatric heart transplantation and the impact that race or insurance status may have on outcomes. What are the factors that explain worse outcomes for black children waiting for a heart transplant? How is the PHTS Racial Disparity Taskforce working to reduce inequities in this field? What role does insurance status have on these outcomes? We speak with noted heart failure and transplantation expert, Dr. Neha Bansal who is Associate Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai about this recent PHTS multicenter study.DOI: 10.1016/j.healun.2022.12.002

Hosts Roz and Alberto are joined by new Editorial Fellow Dr. Sofia Bin to discuss the key articles of the August issue of the American Journal of Transplantation. Dr. Sofia Bin is an assistant professor of medical and surgical sciences at the University of Bologna.   [02:46] Gut microbiome alterations precede graft rejection in kidney transplantation patients [10:31] Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: a multicenter international study Editorial: Graft biopsy reimagined: Integrating morphology and molecular maps [22:20] Does a changing donor pool explain the recent rise in the United States kidney nonuse rate? [32:45] A scintigraphic look at the dead donor rule in donation after the circulatory determination of death with the use of normothermic regional perfusion: A single-center interventional trial Editorial: Normothermic regional perfusion in donation after circulatory determination of death—Confirming the absence of brain reperfusion [37:03] Global variation in living donor liver transplantation practices impacts donor and recipient short-term outcomes: initial insights from the International LDLT Registry

Dr. Chris Wiebe shares his expertise in use of HLA eplet mismatch load in estimating immunologic risk in transplantation. We cover considerations of de novo HLA-DSA formation, donor selection, impacts on post-transplant monitoring protocols, as well as immunosuppression.

What if we could reset our cellular batteries? In this fascinating deep dive into cutting-edge longevity science, Tom Benson from Mitrix Bio reveals how mitochondrial transplantation could revolutionize how we treat age-related diseases and potentially add decades of healthy living to our lives.The conversation begins by exploring the extraordinary nature of mitochondria – those tiny power plants within our cells that generate 95% of our body's energy through molecular rotors functioning like miniature jet turbines. With approximately a quadrillion mitochondria comprising 10% of our body weight, these ancient organelles trace back to a symbiotic merger with our cellular ancestors over a billion years ago.Unlike the nuclear DNA we inherit from both parents, our mitochondrial DNA comes almost exclusively from our mothers, creating fascinating maternal lineage patterns where thousands of family members share identical mitochondrial DNA. As we age, this mitochondrial DNA gradually accumulates damage, with factors like stress, smoking, and medical treatments accelerating deterioration. By our 90s, this decline reaches a critical threshold that appears to drive much of the aging process.The most exciting revelation comes in learning that mitochondria naturally move between cells in our bodies – and scientists are now leveraging this phenomenon through transplantation techniques. By harvesting mitochondria from stem cells grown in bioreactors and reinjecting them, researchers are seeing remarkable improvements in cognition, strength, and immune function in aged mice, essentially restoring youthful cellular energy levels. Human trials are already underway, though still at small scale.For anyone fascinated by the frontiers of longevity science and the quest to not just add years to life, but life to those years, this conversation offers a glimpse into one of the most promising approaches emerging today. https://mitrix.bio/Lies I Taught In Medical School : Free sample chapter- https://www.robertlufkinmd.com/lies/Complete Metabolic Heart Scan (20% off 'LUFKIN20') https://www.innerscopic.com/Fasting Mimicking Diet (20% off) https://prolonlife.com/Lufkin At home blood testing (20% off) https://siphoxhealth.com/lufkinMimio Health (15% off 'LUFKIN') https://mimiohealth.sjv.io/c/5810114/2745519/30611 Web: https://robertlufkinmd.com/X: https://x.com/robertlufkinmdYoutube: https://www.youtube.com/robertLufkinmdInstagram: https://www.instagram.com/robertlufkinmd/LinkedIn: https://www.linkedin.com/in/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinThreads: https://www.threads.net/@robertlufkinmdFacebook: ...

Your Health First: Advancements in Robotic Surgery & Live Liver Donation at Houston MethodistJoin Dr. Joe Galati on this episode of "Your Health First" as he speaks with leading surgeons from Houston Methodist Hospital, Dr. Simon and Dr. Yee Lee Cheah. Broadcasting live from 740 KTRH in Houston and worldwide on the iHeartRadio app every Sunday at 7:00 PM Central, this insightful discussion delves into the groundbreaking work being done in robotic surgery and the current status of the live donor liver transplant program at Houston Methodist.Dr. Simon and Dr. Cheah share their expertise on the numerous benefits of robotic surgery, highlighting the significant advantages for patients and the remarkable advancements in technology over the past 5-10 years. They also provide a comprehensive overview of the meticulous patient selection process for live liver donors and detail the structured program at Houston Methodist Hospital.Don't miss this opportunity to learn about the cutting-edge surgical techniques and life-saving transplant procedures making a difference in patient care.For more information:Dr. Simon & Dr. Cheah: www.houstonmethodist.orgDr. Joe Galati: www.drjoegalati.comGuest Biographies:Dr. Simon:Dr. Simon is a highly accomplished surgeon with a specialization in abdominal transplantation and hepatobiliary surgery. She earned her medical degree with honors from University College Cork Faculty of Medicine in Ireland in 2002 and completed her general surgery residency at Brown University Program, Rhode Island Hospital. Dr. Simon further honed her expertise with a research fellowship in Diagnostic Imaging at Brown University and an ASTS-certified fellowship in Abdominal Transplantation and Hepatobiliary Surgery at Lahey Hospital & Medical Center. Her clinical interests are extensive, encompassing both benign and malignant tumors of the liver, bile duct, and pancreas, including hepatocellular carcinoma and Klatskin tumors. She is also deeply involved in kidney transplantation, living and deceased donor liver transplantation, pancreatic carcinoma, robotic surgery, and surgery for portal hypertension. Dr. Simon is board-certified in general surgery by the American Board of Surgery and is a Fellow of the American College of Surgeons (FACS).Dr. Yee Lee Cheah:Dr. Yee Lee Cheah is a distinguished surgeon who joined the J.C. Walter Jr. Transplant Center at Houston Methodist Hospital in 2022. She graduated with honors from the Royal College of Surgeons in Ireland in 2000 and completed her General Surgery Residency at the Brown University Program. Dr. Cheah further specialized with an ASTS-accredited fellowship in Transplantation & Hepatobiliary Surgery at the Lahey Clinic. Prior to Houston Methodist, she played a pivotal role at the Asian American Liver Centre at Gleneagles Hospital, the largest adult living donor liver transplantation (LDLT) center in Southeast Asia, before returning to LHMC to develop their LDLT and robotic surgery programs. Her expertise lies in living donor liver transplantation, robotic transplantation, HPB surgery for benign and malignant disorders, and nutrition therapy for surgical patients. Dr. Cheah's main research interests are centered on living donor safety and robotic surgery. She has held faculty positions at Brown University and Tufts University and served as an Adjunct Assistant Professor at the National University of Singapore. Hosted on Acast. See acast.com/privacy for more information.

Alles Gute (nachträglich) zum Geburtstag, Heiko "Snäcki" Postel. Er will sich im Sommer Haare einpflanzen lassen. Die Freeses schenken ihm ein paar davon, beziehungsweise das Geld dafür. Jederzeit und so oft ihr wollt: Die NDR 2 Kult-Comedy direkt aus dem Mehrgenerationen-Haushalt der Familie Freese. Die Lasziv-zupackende Oma Rosi, Helikopter-Mama Bianca, Sohn Svenni und Untermieter und Labertasche Heiko: Die besten Folgen bekommt ihr jeden Morgen in der ARD Audiothek.

Hosts Roz and Alberto discuss the key articles of the July issue of the American Journal of Transplantation. [03:48] Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: an intention-to-treat analysis of long-term outcomes [13:42] 10 degree C static storage of porcine donation after circulatory death livers improves biliary viability and mitigates ischemia-reperfusion injury [22:20] Fewer medullary pyramids in the living kidney donor are associated with graft failure in the recipient [33:35] Microvascular inflammation in kidney allografts: New directions for patient management MOMOT (Mouse Models in Transplant) articles: Can mouse kidney transplant models inform mechanisms of injury and acceptance in clinical kidney transplantation? Best practices in islet transplantation in mice

This week we speak with congenital heart surgeon T. Konrad Rajab of Arkansas Children's Hospital about a recent report he co-authored on piglet experiments on partial heart transplantation. How did transplanted heart valves grow in comparison to standard homografts and how did the valvular function differ with time? Is there a minimum dose of immunosuppresion that can protect these valves and can this dose be lower than full heart transplantation immunosuppresion therapy? Is partial heart transplantation considered a potential life-long approach to valve replacement or mostly something used to allow for growth of valves during childhood? What do we know about the world's limited experience in humans of this approach? Dr. Rajab shares the answers this week in an exciting 'sci-fi' episode. The future is now.https://doi.org/10.1016/j.jacbts.2024.10.015

Should animals ever be used as spare parts for humans? PETA Sr. VP Kathy Guillermo was interviewed by CNN about xenotransplantation.  Listen to what she had to say about the experience and the hope that her views are represented fairly.  See PETA represent the ethical perspective on xenotransplantation in the CNN documentary "Animal Pharm," which premieres Sunday, May 17. Find out more about xenotransplantation, go to PETA.org The PETA Podcast PETA, the world's largest animal rights organization, is 9 million strong and growing. Hosted by Emil Guillermo.  Contact us at PETA.org Music provided by CarbonWorks. Go to Apple podcasts and subscribe. Contact and follow host Emil Guillermo and get the podcast on YouTube. www.YouTube.com/@emilamok1 Please subscribe, rate, and review wherever you get your podcasts. Thanks for listening to THE PETA PODCAST! Originally released May 14, 2025,  ©PETA, Emil Guillermo 2023-25  

In this extraordinary episode, Prue shares her remarkable 11-year journey to motherhood, culminating in becoming the third woman in Australia to give birth following a uterus transplant. Her story is one of incredible perseverance, medical innovation, and the profound desire to become a mother against seemingly impossible odds. If you've been considering joining over 6000 families who have prepared for birth with confidence through The Birth Class now's your chance. You can enjoy 20% off in our Mother’s Day Sale with the code: MUM25Inside The Birth Class you’ll enjoy: 10 comprehensive audio lessons 5 guided meditations for pregnancy and birth 70-page detailed workbook Birth partner cheat sheet Birth positions poster Hospital bag checklist Birth preferences template Lifetime access Save 20% Now [ Code: MUM25 ] Sale ends 15th of May at midnight and applies to all our courses!See omnystudio.com/listener for privacy information.